Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | Treatment options for leiomyosarcoma

Javier Martin Broto, MD, PhD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, discusses treatment options for leiomyosarcoma. These include resection or fast relief via a combination of doxorubicin and dacarbazine. In asymptomatic patients with metastatic disease, but no prospective surgical rescue, first-line doxorubicin monotherapy could be adequate. Second-line treatment presents more possibilities, such as trabectedin or gemcitabine combinations. Research aims to improve long term survival and a higher proportion of surgical rescue, even in metastatic locally advanced cases. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.